Regulatory affairs scientists and CMC leads preparing or reviewing IND or CTA submissions for cell and gene therapy products need to assess the completeness and compliance of Module 3 (Quality) sections against FDA CDER/CBER expectations and EMA Guidelines specific to ATMPs (Advanced Therapy Medicinal Products). They face highly complex, product-specific regulatory requirements that differ substantially from small molecule or conventional biologic guidance.